Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,752,875
  • Shares Outstanding, K 106,374
  • Annual Sales, $ 761,410 K
  • Annual Income, $ 99,650 K
  • EBIT $ 45 M
  • EBITDA $ 42 M
  • 60-Month Beta 0.29
  • Price/Sales 5.03
  • Price/Cash Flow 39.85
  • Price/Book 5.84

Options Overview Details

View History
  • Implied Volatility 52.66% (-5.24%)
  • Historical Volatility 78.81%
  • IV Percentile 21%
  • IV Rank 15.60%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 15) 2.64 (7.38%)
  • Put/Call Vol Ratio 10.39
  • Today's Volume 843
  • Volume Avg (30-Day) 2,186
  • Put/Call OI Ratio 1.09
  • Today's Open Interest 33,220
  • Open Int (30-Day) 43,230
  • Expected Range 33.06 to 38.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.40
  • Prior Year 0.17
  • Growth Rate Est. (year over year) -264.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.66 +24.53%
on 02/19/26
41.92 -14.86%
on 02/10/26
-4.44 (-11.06%)
since 02/04/26
3-Month
28.66 +24.53%
on 02/19/26
89.00 -59.90%
on 12/15/25
-48.97 (-57.84%)
since 12/04/25
52-Week
28.66 +24.53%
on 02/19/26
117.33 -69.58%
on 03/31/25
-20.30 (-36.26%)
since 03/04/25

Most Recent Stories

More News
Law Offices of Frank R. Cruz Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept”...

CORT : 35.69 (+1.16%)
Lost Money on Corcept Therapeutics Incorporated(CORT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK , March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated" or the "Company") (NASDAQ: CORT) of...

CORT : 35.69 (+1.16%)
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who...

CORT : 35.69 (+1.16%)
Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline

Lawsuit Alleges Corcept Ignored Repeated FDA Warnings Against Filing Relacorilant NDA; Stock Plunged 50% on Revealed "Evidence Gaps"

CORT : 35.69 (+1.16%)
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated Lawsuit - CORT

NEW YORK , March 3, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  Corcept Therapeutics Incorporated (NASDAQ: CORT).

CORT : 35.69 (+1.16%)
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

NEW YORK , March 2, 2026 /PRNewswire/ -- 

CORT : 35.69 (+1.16%)
Deadline Approaching: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Law Offices of Howard G. Smith reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Corcept Therapeutics...

CORT : 35.69 (+1.16%)
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , March 2, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics...

CORT : 35.69 (+1.16%)
Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT

LOS ANGELES , March 2, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Corcept Therapeutics Incorporated ("Corcept " or "the Company") (NASDAQ:...

CORT : 35.69 (+1.16%)
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK and NEW ORLEANS , Feb. 27, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial...

CORT : 35.69 (+1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 37.31
2nd Resistance Point 36.68
1st Resistance Point 36.19
Last Price 35.69
1st Support Level 35.06
2nd Support Level 34.43
3rd Support Level 33.94

See More

52-Week High 117.33
Fibonacci 61.8% 83.46
Fibonacci 50% 73.00
Fibonacci 38.2% 62.53
Last Price 35.69
52-Week Low 28.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar